Innogenetics N.v.

Rhein Biotech Gesellschaft Fur Neue Biotechnologische Prozesse Und Produkte Mbh

Artes Biotechnology Gmbh

Manfred Suckow

Erik Depla

Erwin Sablon

Fons Bosman

Geert Deschamps

Gert Verheyden

Isabelle Samson

Michael Piontek

The present invention relates to a deoxyribonucleic acid (DNA) comprising at least one promoter sequence, which is derived from a wild-type promoter of a methyltrophic yeast, whose transcription efficiency is modulated in comparison to the efficiency of the wild-type promoter by inserting or modifying a DNA binding site. The invention also relates to host cells, expression vectors, kits and methods for producing proteins while using the inventive DNA, as well as to different uses of the same and to a method for producing expression vectors.

Promoters having a modified transcription efficiency and derived from methyltrophic yeast

The current invention relates to HCV envelope proteins or parts thereof which are the product of expression in eukaryotic cells. More particularly said HCV envelope proteins are characterized in that on average up to 80% of their N-glycosylation sites are core-glycosylated. Of these N-glycosylated sites more than 70% are glycosylated with an oligomannose having a structure defined by Man(8 to 10)-GlcNAc(2). Furthermore, the ratio of the oligomannose with structure Man(7)-GlcNAc(2) over the oligomannose with structure Man(8)-GlcNAc(2) is less than or equal to 0.45. Less than 10% of the oligomannoses is terminated with an &#x3b1;1,3 linked mannose. The HCV envelope proteins of the invention are particularly suited for diagnostic, prophylactic and therapeutic purposes. A suitable eukaryotic cell for production of the HCV envelope proteins of the invention is acell.

Core-glycosylated HCV envelope proteins

Growing community of inventors

Düsseldorf, Germany

Manfred Suckow